PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Position Lifted by Shell Asset Management Co.

Shell Asset Management Co. grew its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCTGet Rating) by 87.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,925 shares of the biopharmaceutical company’s stock after buying an additional 1,362 shares during the period. Shell Asset Management Co.’s holdings in PTC Therapeutics were worth $117,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of PTCT. DekaBank Deutsche Girozentrale lifted its holdings in PTC Therapeutics by 9.8% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 16,800 shares of the biopharmaceutical company’s stock worth $627,000 after buying an additional 1,500 shares during the last quarter. New York State Common Retirement Fund lifted its holdings in PTC Therapeutics by 1.3% during the 1st quarter. New York State Common Retirement Fund now owns 63,653 shares of the biopharmaceutical company’s stock worth $2,375,000 after buying an additional 787 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in PTC Therapeutics by 5.4% during the 1st quarter. Fisher Asset Management LLC now owns 214,974 shares of the biopharmaceutical company’s stock worth $8,021,000 after buying an additional 11,000 shares during the last quarter. Sector Gamma AS bought a new position in PTC Therapeutics during the 1st quarter worth approximately $2,980,000. Finally, Teacher Retirement System of Texas lifted its holdings in PTC Therapeutics by 6.4% during the 1st quarter. Teacher Retirement System of Texas now owns 13,027 shares of the biopharmaceutical company’s stock worth $486,000 after buying an additional 789 shares during the last quarter.

Insider Buying and Selling at PTC Therapeutics

In other PTC Therapeutics news, VP Mark Elliott Boulding sold 1,176 shares of PTC Therapeutics stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $55.00, for a total transaction of $64,680.00. Following the sale, the vice president now owns 61,110 shares of the company’s stock, valued at approximately $3,361,050. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

PTCT has been the topic of a number of research analyst reports. Citigroup assumed coverage on PTC Therapeutics in a report on Thursday, September 1st. They set a “buy” rating and a $70.00 target price on the stock. Cowen cut their price target on PTC Therapeutics to $44.00 in a report on Tuesday, November 1st. Morgan Stanley cut their price target on PTC Therapeutics from $54.00 to $40.00 and set an “equal weight” rating on the stock in a report on Friday, October 28th. StockNews.com raised PTC Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, October 31st. Finally, Jefferies Financial Group assumed coverage on PTC Therapeutics in a report on Monday, September 12th. They issued a “buy” rating and a $62.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $55.50.

PTC Therapeutics Price Performance

Shares of PTC Therapeutics stock opened at $40.48 on Friday. The business’s fifty day moving average price is $45.90 and its two-hundred day moving average price is $42.56. The company has a market capitalization of $2.91 billion, a P/E ratio of -5.42 and a beta of 0.43. PTC Therapeutics, Inc. has a 1-year low of $25.01 and a 1-year high of $55.58.

About PTC Therapeutics

(Get Rating)

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases.

See Also

Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCTGet Rating).

Institutional Ownership by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.